Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Depreciation & Amortization (CF): 2019-2025

Historic Depreciation & Amortization (CF) for Biodesix (BDSX) over the last 6 years, with Sep 2025 value amounting to $1.4 million.

  • Biodesix's Depreciation & Amortization (CF) fell 5.83% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 million, marking a year-over-year increase of 8.09%. This contributed to the annual value of $5.8 million for FY2024, which is 73.47% up from last year.
  • As of Q3 2025, Biodesix's Depreciation & Amortization (CF) stood at $1.4 million, which was down 2.09% from $1.4 million recorded in Q2 2025.
  • In the past 5 years, Biodesix's Depreciation & Amortization (CF) registered a high of $1.5 million during Q3 2024, and its lowest value of $746,000 during Q1 2021.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $1.4 million (2024), whereas its average is $1.2 million.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first declined by 13.55% in 2023, then skyrocketed by 90.92% in 2024.
  • Quarterly analysis of 5 years shows Biodesix's Depreciation & Amortization (CF) stood at $855,000 in 2021, then grew by 5.03% to $898,000 in 2022, then increased by 8.80% to $977,000 in 2023, then surged by 48.31% to $1.4 million in 2024, then dropped by 5.83% to $1.4 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $1.4 million for Q3 2025, versus $1.4 million for Q2 2025 and $1.4 million for Q1 2025.